Literature DB >> 3665325

The influence of food on the bioavailability of a slow release theophylline preparation.

J J Thebault1, J M Aiache, F Mazoyer, J M Cardot.   

Abstract

Food-induced changes in the absorption of Theostat 300, a controlled release formulation of theophylline, have been studied in healthy volunteers. This open, randomised, 3-way, single-dose study involved 12 volunteers who received the drug either while fasting, or with a standardised low-fat (10g), or high-fat (60g) breakfast. Each subject was studied over a 3-week period, with 3 separate days of oral treatment and a 7-day washout period between treatments. The results showed no differences in AUC0-24 and tmax values between the 3 kinds of diet. The only differences observed concerned absorption. Food intake increased Cmax values by 20%. The steady-state peak concentration obtained by means of simulated plasma levels was not influenced by food intake. This slight food-drug interaction of Theostat 300 seemed to be of no clinical significance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3665325     DOI: 10.2165/00003088-198713040-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  15 in total

1.  Rapid assay for theophylline in clinical samples by reversed-phase high-performance liquid chromatography.

Authors:  P J Naish; M Cooke; R E Chambers
Journal:  J Chromatogr       Date:  1979-08-21

2.  An incremental method for the study of the absorption of drugs whose kinetics are described by a two-compartment model: estimation of the microscopic rate constants.

Authors:  A Gerardin; D Wantiez; A Jaouen
Journal:  J Pharmacokinet Biopharm       Date:  1983-08

3.  Greatly enhanced bioavailability of theophylline on postprandial administration of a sustained release tablet.

Authors:  M Lagas; J H Jonkman
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Effect of food on the bioavailability and pattern of release of a sustained-release theophylline tablet.

Authors:  N H Leeds; P Gal; A A Purohit; J B Walter
Journal:  J Clin Pharmacol       Date:  1982-04       Impact factor: 3.126

5.  Food-induced dose dumping of Theo-24.

Authors:  L Hendeles; K Thakker; M Weinberger
Journal:  Am Pharm       Date:  1985-10

6.  Delay in the absorption rate of theophylline from a sustained release theophylline preparation caused by food.

Authors:  S Pedersen
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

Review 7.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

8.  Food-induced changes in theophylline absorption from controlled-release formulations. Part II. Importance of meal composition and dosing time relative to meal intake in assessing changes in absorption.

Authors:  A Karim; T Burns; D Janky; A Hurwitz
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

9.  Food-induced changes in theophylline absorption from controlled-release formulations. Part I. Substantial increased and decreased absorption with Uniphyl tablets and Theo-Dur Sprinkle.

Authors:  A Karim; T Burns; L Wearley; J Streicher; M Palmer
Journal:  Clin Pharmacol Ther       Date:  1985-07       Impact factor: 6.875

10.  Absorption of theophylline from enteric coated and sustained release formulations in fasted and non-fasted subjects.

Authors:  M A Osman; R B Patel; D S Irwin; P G Welling
Journal:  Biopharm Drug Dispos       Date:  1983 Jan-Mar       Impact factor: 1.627

View more
  2 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline.

Authors:  J L Brazier; Y Benchekroun; A Gillet; C Andre
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.